Anzeige
Mehr »
Login
Sonntag, 19.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1H65A | ISIN: NL0010391025 | Ticker-Symbol: PHGN
Tradegate
17.05.24
18:03 Uhr
0,850 Euro
-0,003
-0,29 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PHARMING GROUP NV Chart 1 Jahr
5-Tage-Chart
PHARMING GROUP NV 5-Tage-Chart
RealtimeGeldBriefZeit
0,8420,87419:04
0,8490,85717.05.

Aktuelle News zur PHARMING Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiPharming Group N.V. - 6-K, Report of foreign issuer2
MiPharming Group N.V.: Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025249THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE...
► Artikel lesen
MoEarnings call: Pharming Group reports strong Q1 growth, eyes global expansion4
08.05.Pharming Group NV reports results for the quarter ended in January - Earnings Summary2
08.05.Pharming Group uproots angioedema gene therapy collab with Orchard4
08.05.Pharming GAAP EPS of -$0.01 misses by $0.02, revenue of $55.6M misses by $14.47M1
08.05.Pharming Group N.V. - 6-K, Report of foreign issuer1
08.05.Pharming Group N.V.: Pharming Group reports first quarter 2024 financial results and provides business update418First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST®RUCONEST® revenues...
► Artikel lesen
24.04.Pharming Group N.V. - 6-K, Report of foreign issuer2
24.04.Pharming Group N.V.: Pharming Group to report first quarter 2024 financial results on May 8155Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results...
► Artikel lesen
24.04.Pharming Group N.V.: Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards4
19.04.Pharming Group N.V.: Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025725NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden...
► Artikel lesen
18.04.Pharming Group N.V.: Pharming Group announces the placement of €100 million convertible bonds due 2029319NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden...
► Artikel lesen
18.04.Pharming Group N.V.: Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025228NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Pharming...
► Artikel lesen
08.04.Pharming Group N.V.: Pharming announces completion of enrollment in pediatric clinical trial of leniolisib170This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming Group...
► Artikel lesen
04.04.Pharming Group N.V. - 6-K, Report of foreign issuer1
04.04.Pharming Group N.V. - 20-F, Annual and transition report of foreign private issuers2
04.04.Pharming Group N.V.: Pharming Group announces the 2024 Annual General Meeting of Shareholders2
04.04.Pharming Group N.V.: Pharming Group announces the filing of its 2023 Annual Report and Form 20-F3
15.03.Pharming reports Q4 results4
Seite:  Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1